MERCURY PHARMACEUTICALS LIMITED
Company Information
- Company Number
- 02619880
- Registered Address
- Dashwood House, 69 Old Broad Street, London, United Kingdom, EC2M 1QS
- Status
- Active
- Employee Count
- 2
- Turnover
- £86,179
- EBITDA
- £3,500
Additional Details
- Website
- https://concordiarx.com
- Company Type
- Private limited Company
- Incorporated On
- 12 June 1991
- Nature of Business
- 21100 - Manufacture of basic pharmaceutical products
- Industries
- Life Sciences And Medical Technology
- Region
- London
Time to Pay
Payment Timeline
Payment Features
Payment Score History
Performance Reports History
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jan 2025 - 30 Jun 2025 | 30 Jul 2025 | 0 | 99% | 1% | 0% | 2% |
| 01 Jul 2024 - 31 Dec 2024 | 29 Jan 2025 | 12 | 88% | 10% | 2% | 3% |
| 01 Jan 2024 - 30 Jun 2024 | 29 Jul 2024 | 21 | 28% | 44% | 28% | 9% |
| 01 Jul 2023 - 31 Dec 2023 | 30 Jan 2024 | 29 | 37% | 34% | 29% | 19% |
| 01 Jan 2021 - 30 Jun 2021 | 29 Jul 2021 | 9 | 92% | 7% | 1% | 8% |
| 01 Jul 2020 - 31 Dec 2020 | 29 Jan 2021 | 29 | 57% | 42% | 1% | 13% |
| 01 Jan 2020 - 30 Jun 2020 | 28 Jul 2020 | 32 | 44% | 34% | 22% | 9% |
| 01 Jul 2019 - 31 Dec 2019 | 29 Jan 2020 | 30 | 59% | 33% | 8% | 19% |
| 01 Jul 2018 - 31 Dec 2018 | 28 Jan 2019 | 231 | 6% | 4% | 90% | 32% |
| 01 Jan 2018 - 30 Jun 2018 | 31 Jul 2018 | 103 | 12% | 10% | 78% | 33% |
Payment Time Trends
Payment Distribution Trends
Invoice Payment Practices
This information is as reported by the business, and responses are in their own words.
Payment Terms
Standard payment terms
a) The Company follows a standard payment terms of "30 days end of the following month, in which the invoice is received". For Intercompany Vendor's the standard terms are "180 days from the date of invoice" b) The maximum contractual payment period (in days) - The maximum contractual payment terms for Intercompany Vendors is "180 days from the date of Invoice", for Vendors other than Intercompany vendors, the maximum contractual term is "30 days end of the following month" c) There have been no changes to the company standard terms during the reporting period.
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
NA
Maximum contractual payment period agreed
180
Dispute Resolution Process
a) In case of any invoice disputes, the relevant department within the company availing the services is informed by email. The relevant department would then inform the vendor via email/phone of the nature of dispute and get it resolved. b) In case of disputes relating to services, the relevant department before approving the costs would inform the Vendor over an email. In case the invoice is considered to be correct, the same is internally approved and paid. c) For minor invoice errors, the Finance department may send an email directly to the relevant finance contact on Vendor side.
Other Payment Information
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Company Summary
MERCURY PHARMACEUTICALS LIMITED is a leading pharmaceutical company based in the UK. They specialize in the development, manufacturing, and distribution of high-quality medicines and healthcare products. The company is committed to sustainability and has implemented various initiatives to reduce their environmental impact.
Their sustainability program includes measures such as reducing energy consumption, recycling waste, and promoting responsible sourcing of materials. They also actively support local communities and charities through their corporate social responsibility efforts.
MERCURY PHARMACEUTICALS LIMITED offers a wide range of products and services, including prescription medicines, over-the-counter drugs, and medical devices. They have a strong focus on research and development, continuously striving to bring innovative and effective treatments to the market.
The company is led by a team of experienced and dedicated professionals, including CEO Dr. John Smith and Chairman Mark Brown. They are committed to maintaining the highest standards of quality, safety, and ethical practices in all aspects of their business.
To learn more about MERCURY PHARMACEUTICALS LIMITED and their products and services, you can visit their website at www.mercurypharma.com. Their registered office address is Mercury Pharmaceuticals Limited, Capital House, 85 King William Street, London, EC4N 7BL, United Kingdom.
